Connect with us


Human trials begin for low-cost COVID-19 vaccine that could help extend global manufacturing access



AUSTIN, TX — A vaccine that recently entered human trials in Vietnam and Thailand and is slated for a clinical study in Brazil could prove key to boosting global vaccination efforts through affordable vaccine manufacturing in countries currently dependent on imported vaccines.

The vaccine, NDV-HXP-S, is the result of a partnership between the University of Texas at Austin, the Icahn School of Medicine at Mount Sinai in New York and global partners, according to UT.

The vaccine can be stored at 2 to 8 degrees Celsius and is made in eggs, a method also used for flu vaccine manufacturing, meaning the manufacturing capacity already exists in the countries involved with trials. The vaccine uses a highly stabilized spike coronavirus protein, HexaPro, which was engineered by three faculty labs at UT. Hexapro was found in earlier research to be promising for use in robust vaccines, UT said.

Other COVID-19 vaccines also use stabilized proteins, but NDV-HXP-S is HexaPro’s first use in a vaccine in human trials.